JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Strona główna・Stock List・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Closed

SectorHealthcare

5.9 -3.28

Buy Sell

Overview

Share price change

24h

Current

Min

5.9

Max

6.23

Key metrics
By Trading Economics
Income	30M -36M
Sales	1.6M 31M
Profit margin	-117.018
Employees	181
EBITDA	24M -40M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+271.64% upside

Dividends
By Dow Jones
Next Earnings	29 paź 2025

Market Stats
By TradingEconomics
Market Cap	-121M 683M
Previous open	9.18
Previous close	5.9

News Sentiment

By Acuity

50%

162 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

6.26 / 7.47 Support & Resistance

Day One Biopharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 sie 2025, 17:49 UTC

Major Market Movers

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 sie 2025, 17:18 UTC

Major Market Movers

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 sie 2025, 16:25 UTC

Earnings

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 sie 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 sie 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 sie 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 sie 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 sie 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 sie 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 sie 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 sie 2025, 20:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 sie 2025, 20:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 sie 2025, 20:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement 2Q Rev $25.8M >EXOD

11 sie 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 sie 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 sie 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 sie 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 sie 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 sie 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 sie 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 sie 2025, 16:42 UTC

Acquisitions, Mergers, Takeovers

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 sie 2025, 16:27 UTC

Acquisitions, Mergers, Takeovers

BBVA Says Sabadell Offer Remains in Effect

11 sie 2025, 16:26 UTC

Acquisitions, Mergers, Takeovers

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 sie 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

Banco de Sabadell Announced TSB Sale on July 1

11 sie 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer Comparison

Price change

Day One Biopharmaceuticals Inc Forecast

Price Target

By TipRanks

271.64% upside

12 Months Forecast

Average 22.67 USD 271.64%

High 34 USD

Low 16 USD

Based on 8 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Day One Biopharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.26 / 7.47Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

162 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.